Advanced Tumors
Conditions
Brief summary
The primary objectives of this study are to characterize the safety and tolerability of CS23546 and to evaluate the pharmacokinetic (PK) characteristics and recommended phase 2 dose (RP2D) of CS23546 in subjects with advanced tumors.
Detailed description
This study is a single arm, open phase I trial, consisting of a dose escalation phase (single dose+multiple doses) and a dose expansion phase, accompanied by pharmacokinetic and pharmacokinetic studies. The first visit period (21 days) of single dose and multiple doses during the dose-increasing phase is the DLT observation period.
Interventions
DRUGCS23546
Tablets administered orally.
Sponsors
Chipscreen Biosciences, Ltd.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Key Inclusion Criteria: 1. Male or female and ≥18 years of age on day of signing informed consent. 2. Histologically or cytologically confirmed unresectable advanced recurrent/refractory solid tumor or lymphoma that is failure or or intolerant of all standard therapy or for which no standard therapy is available. 3. Individuals are required to provide tumor tissue samples for prospective detection of Programmed cell death 1 ligand 1 (PD-L1) expression and/or Microsatellite instability (MSI) / the DNA mismatch repair (MMR) status. Subjects who cannot be provided during the dose escalation phase will be evaluated by the researchers and sponsors before deciding whether to enroll. 4. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. 5. Adequate organ function. 6. Life expectancy ≥12 weeks. 7. Dose expansion phase: Cohort 1, Subjects with urothelial carcinoma. Cohort 2, Subjects with Extranodal NK/T-cell lymphoma (NKTCL). Cohort 3, Subjects with soft tissue sarcoma. Cohort 4, Subjects with PD-L1 expression positive and/or microsatellite-instability-high (MSI-H) / mismatch-repair-deficient (dMMR) advanced solid tumors or lymphoma Key
Exclusion criteria
1. Received anti-tumor therapy (including but not limited to chemotherapy, targeted therapy, anti angiogenic therapy, immunotherapy, cell therapy, radiotherapy, tumor embolization, etc.) or experimental drugs/devices that have not been approved for marketing within 28 days before the first medication. 2. History of ≥ Grade 3 immune related Adverse Events (irAEs) or termination of treatment due to irAEs during prior treatment with Programmed death 1 (PD-1) /PD-L1 antibody. 3. Active autoimmune diseases present during the screening period and systemic treatment was received within 2 years before the first medication. Individuals who only require hormone replacement therapy (such as thyroxine, insulin, or physiological corticosteroids used for adrenal or pituitary insufficiency) can be enrolled. 4. Presence of central nervous system metastasis and/or meningeal metastasis. 5. Dose expansion phase: Subjects with solid tumors or lymphoma who have previously received PD-L1 inhibitors and belong to primary resistance.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Dose Limiting Toxicities (DLTs) | Day 1 through Day 27 | DLT: Number of patients experienced any dose limited toxicity. MTD: One level lower than the dose level at which dose escalation was terminated due to DLT reasons. |
| Maximum Tolerated Dose (MTD) | Day 1 through Day 27 | MTD: One level lower than the dose level at which dose escalation was terminated due to DLT reasons. |
| Time to Cmax (Tmax) | up to Day 1 of cycle 5 (each cycle is 21 days) | Time to reach the Cmax for CS23546. |
| Maximum plasma concentration (Cmax) | up to Day 1 of cycle 5 (each cycle is 21 days) | Maximum observed plasma concentration for CS23546. |
| Area Under the Curve (AUC) | up to Day 1 of cycle 5 (each cycle is 21 days) | Area Under the Plasma Concentration-time Curve From Zero Time to the Last Measurable Point for CS23546. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The inhibitory activity of Programmed cell death 1 ligand 1 (PD-L1) | up to Day 1 of cycle 5 (each cycle is 21 days) | — |
| Interferon gamma (IFN-γ) | up to Day 1 of cycle 5 (each cycle is 21 days) | Plasma concentration for IFN-γ. |
| Free PD-L1 | up to Day 1 of cycle 5 (each cycle is 21 days) | Plasma concentration for free PD-L1. |
| C-X-C motif chemokine 9 (CXCL9) | up to Day 1 of cycle 5 (each cycle is 21 days) | Plasma concentration for CXCL9. |
| C-X-C motif chemokine 10 (CXCL10) | up to Day 1 of cycle 5 (each cycle is 21 days) | Plasma concentration for CXCL10. |
| Objective response rate (ORR) | Until 28 days after the last dose of the study drug | Efficacy evaluation indicators for research. |
| Disease control rate (DCR) | Until 28 days after the last dose of the study drug | Efficacy evaluation indicators for research. |
| Duration of response (DOR) | Until 28 days after the last dose of the study drug | Efficacy evaluation indicators for research. |
| Time to progression (TTP) | Until 28 days after the last dose of the study drug | Efficacy evaluation indicators for research. |
| time to progressive disease (TTR) | Until 28 days after the last dose of the study drug | Efficacy evaluation indicators for research. |
| Progression free survival (PFS) | Until 28 days after the last dose of the study drug | Efficacy evaluation indicators for research. |
| Overall survival (OS) | Until 28 days after the last dose of the study drug | Efficacy evaluation indicators for research. |
| Safety indicators: adverse events (AE) | Until 28 days after the last dose of the study drug | The incidence and severity of adverse events (AE) (according to CTCAE v5.0). |
Countries
China
Contacts
CONTACTXinhao Wang
PRINCIPAL_INVESTIGATORHuiqiang Huang, Ph.D.
Sun Yat-sen University Cancer Cancer
Outcome results
None listed